Cargando…
Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia
BACKGROUND: The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations. METHODS: A total of 197 juvenile patients were enrolled i...
Autores principales: | Alexeeva, Ekaterina I., Namazova-Baranova, Leyla S., Bzarova, Tatyana M., Valieva, Saniya I., Denisova, Rina V., Sleptsova, Tatyana V., Isaeva, Kseniya B., Chomahidze, Alexandra M., Taibulatov, Nikolay I., Fetisova, Anna N., Karaseva, Anna V., Baranov, Alexandr A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471744/ https://www.ncbi.nlm.nih.gov/pubmed/28615036 http://dx.doi.org/10.1186/s12969-017-0178-9 |
Ejemplares similares
-
Quality of life in patients with juvenile arthritis: adalimumab might make a difference
por: Denisova, Rina, et al.
Publicado: (2011) -
Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014) -
Juvenile idiopathic arthritis is a diagnosis of exclusion
por: Alexeeva, Ekaterina, et al.
Publicado: (2014) -
P02-011 - TRAPS syndrome debuted as systemic JIA
por: Sleptsova, T, et al.
Publicado: (2013) -
Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)